Answers are grounded in this paper and cite their sources.
Plasma is a rich and accessible source for biomarkers. The analytical challenge of the steep dynamic range was recently addressed using enrichment technologies. Enrichment technologies have been shown to be sensitive to preanalytical variables, making this an active area of research. We established the P2 enrichment system as high-performing and robust for large scale studies, with reproducible identifications and precision across batches, days, operators and laboratories. We characterized P2-based enrichment for preanalytical variables (eight blood collection types, centrifugation, freeze-thaw and pathogen inactivation). K2EDTA-plasma resulted in the deepest proteome coverage with about 6000 protein groups on the timsTOF HT. We spiked 16 heavy-labelled proteins into platelet-poor and platelet-contaminated plasma. Importantly, linearity, accuracy, and precision were high in both platelet-poor and platelet-contaminated plasma for both P2-enriched and neat preparations. In a cancer cohort, we demonstrated that 97% of differentially abundant proteins retained the same direction of regulation after P2-based enrichment compared with the neat preparation. Differentially abundant proteins identified in a colorectal cancer pilot cohort remained largely conserved after platelet contamination, including previously reported biomarkers. We demonstrated that P2-based enrichment enables deep, large scale proteome profiling and preserves biological information despite preanalytical variation. Candidates emerging from P2-based discovery can be validated in independent cohorts with targeted assays.
No takes yet. Share an insight, caveat, or question.
Viodé et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: